Solitomab

Drug Overview

Solitomab is a modern, high-tech cancer medication designed to help the body’s own immune system find and destroy tumor cells. It belongs to a cutting-edge group of drugs called Bispecific T-cell Engagers, or BiTEs. This medicine is a prime example of Immunotherapy and Targeted Therapy because it acts as a “Smart Drug,” specifically bridging the gap between a patient’s defense cells and the cancer itself.

In the world of oncology, solitomab represents a new way to treat solid tumors that have been difficult to target with traditional medicine. Because it is highly specific, it seeks out a marker called EpCAM which is found on many different types of cancer cells, while trying to leave healthy cells alone.

• Generic name: Solitomab (also known as AMG 110 or MT110)
• US Brand names: None (Currently an investigational drug)
• Drug Class: Bispecific T-cell Engager (BiTE); Immunotherapy
• Route of Administration: Continuous Intravenous (IV) infusion
• FDA Approval Status: Investigational (Not yet approved for general medical use)

What Is It and How Does It Work? (Mechanism of Action)

Solitomab works like a “molecular matchmaker.” To understand how it works at the molecular level, imagine the drug has two “hands.” One hand is designed to grab onto a cancer cell, and the other hand is designed to grab onto a T-cell, which is the “soldier” cell of your immune system.

1. The Targeting Hand (Anti-EpCAM): This part of the drug finds and locks onto a protein called Epithelial Cell Adhesion Molecule, or EpCAM. This protein is like a unique flag that is flown in very high amounts on the surface of many solid tumors, such as colon, lung, and breast cancer.
2. The Activating Hand (Anti-CD3): The other part of the drug finds a receptor called CD3 on the surface of your T-cells. Normally, T-cells might walk right past a cancer cell because the cancer is good at hiding.
3. The Bridge: By grabbing both the cancer cell and the T-cell at the same time, solitomab pulls them together into a very tight “immune synapse.” This physical connection sends a powerful signal to the T-cell, telling it to “wake up” and attack. The T-cell then releases toxic chemicals directly into the cancer cell, causing the tumor cell to undergo apoptosis, which is the medical term for programmed cell death.

FDA Approved Clinical Indications

Because solitomab is an investigational drug, it does not currently have official FDA-approved uses for the general public. It is being studied in clinical trials for:

Oncological uses

• Investigational treatment for advanced solid tumors (including colorectal, gastric, and lung cancer).
• Investigational treatment for metastatic breast cancer.
• Research for other epithelial-derived cancers that show high levels of EpCAM.

Non-oncological

• Currently, there are no non-oncological uses for this medication.

Dosage and Administration Protocols

In clinical research settings, solitomab is unique because it must be given as a continuous drip. This is because the drug is very small and would be cleared out of the body too quickly if given as a single shot.

Dose Adjustments

Because this drug is a large biological protein, it is not processed by the liver or kidneys in the same way as a chemical pill. However, if a patient develops a severe immune reaction, the infusion is immediately paused or the speed is slowed down. There are no established dose starting rules for patients with renal (kidney) or hepatic (liver) insufficiency outside of trial protocols, but these organs are checked daily.

Clinical Efficacy and Research Results

Clinical research data from the 2020 to 2025 period have focused on finding the safest dose that still kills cancer cells.

Numerical data from early Phase 1 trials show that solitomab is active in the human body. In studies for advanced gastrointestinal and lung cancers, the drug successfully activated T-cells and caused them to move toward the tumors. While the researchers are still looking for the perfect “sweet spot” dose to maximize survival rates, early numerical results showed that a portion of patients achieved “Stable Disease,” meaning their cancer stopped growing for several months. Current research is focusing on using lower doses in combination with other immunotherapies to see if they can increase the number of patients who see their tumors shrink (the overall response rate).

Safety Profile and Side Effects

Because solitomab activates the immune system so powerfully, the side effects are often related to inflammation.

Black Box Warning

There is no official FDA Black Box Warning for solitomab because it is an investigational drug. However, similar drugs in this class carry warnings for Cytokine Release Syndrome (CRS) and Neurological Events.

Common side effects

These occur in more than 10 percent of patients:

• Fever and chills
• Nausea and vomiting
• Diarrhea
• Feeling very tired (fatigue)
• Increases in liver enzymes (temporary)

Serious adverse events

• Cytokine Release Syndrome (CRS): A severe immune reaction that causes very high fever and low blood pressure.
• Neurotoxicity: Confusion, trouble speaking, or seizures (rare but serious).
• Severe diarrhea and stomach pain.
• Lung inflammation (pneumonitis).

Management strategies

To keep patients safe, doctors often start with a very low dose and “step up” to the full dose over several days. If a patient develops a high fever, the medical team will use steroid medications to calm the immune system down. Because the drug is given via a portable pump, patients are taught how to monitor the pump and check for signs of infection at the needle site.

Research Areas

Solitomab is a major focus in Research Areas involving the “Tumor Microenvironment.” Scientists are studying if this drug can be paired with Checkpoint Inhibitors (like pembrolizumab) to make the T-cells even more aggressive. There is also early research into whether this targeted approach can be used alongside stem cell therapies to help rebuild a patient’s immune system while the drug keeps the cancer at bay. Currently, the most active research is looking for “biomarkers” in the tumor’s supportive tissue (the stroma) that can help doctors predict exactly which patients will respond best to this BiTE therapy.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• A biopsy to confirm the tumor has the EpCAM marker.
• Complete blood count (CBC) to check the number of available T-cells.
• Liver and kidney function tests (ALT, AST, Bilirubin, and Creatinine).
• Baseline neurological exam to check for any existing brain or nerve issues.

Precautions during treatment

Patients should be aware that the infusion pump must stay on 24 hours a day. It is important to stay hydrated and avoid strenuous activity that could dislodge the IV line. Because the drug can cause sudden fatigue or confusion, patients should not drive during the first few days of each treatment cycle.

Do’s and Don’ts list

• Do tell your nurse immediately if you feel hot, shaky, or have trouble breathing.
• Do drink plenty of fluids to help your kidneys and blood pressure.
• Do keep the infusion pump battery charged and the site clean.
• Don’t stop the pump or try to adjust the dose yourself.
• Don’t take new herbal supplements without asking your trial doctor first.
• Don’t ignore a headache or a “fuzzy” feeling in your head, as these can be early signs of neurotoxicity.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Solitomab is an investigational drug and is not approved by the FDA for the treatment of any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment or managing side effects.